Immunoproteasomes and immunosenescence

Aging is a complex process which is accompanied with the decline and the reshaping of different functions of the body. In particular the immune system is characterized, during ageing (immunosenescence) by a remodeling of innate immunity (well preserved, up-regulated) and clonotypical immunity (severely altered) and by the occurrence of a chronic inflammatory process (inflammaging) which are, at least in part, genetically controlled. In this scenario, it can be anticipated that a crucial role is played by age-related structural and functional alterations and modifications of proteasomes and immunoproteasomes, the last being a key component of antigen processing and MHC class I antigen presentation. A variety of experimental data are available, suggesting that proteasomes are affected by age, and that in centenarians they are relatively preserved. On the contrary, few data are available on immunoproteasomes, likely as a consequence of the poverty of suitable cellular models. Lymphoblastoid cell lines from EBV immortalized B cells from old donors is envisaged as a possible model for the study of immunoproteasomes in humans and their changes with age. Thus, basic questions such as those related to possible consequences, for immune responses in infectious diseases and cancer, of age-related alterations of antigen processing and presenting, change with age of self-antigen repertoire, and the genetic basis of immunoproteasome activity and its change with age, remain largely unanswered.

[1]  C. Franceschi,et al.  The −174 C/G locus affects in vitro/in vivo IL-6 production during aging , 2002, Experimental Gerontology.

[2]  C. Franceschi,et al.  A gender–dependent genetic predisposition to produce high levels of IL‐6 is detrimental for longevity , 2001, European journal of immunology.

[3]  C. Franceschi,et al.  A stochastic model for CD8(+)T cell dynamics in human immunosenescence: implications for survival and longevity. , 2001, Journal of theoretical biology.

[4]  C. Franceschi,et al.  Fibroblast cultures from healthy centenarians have an active proteasome , 2000, Experimental Gerontology.

[5]  D. W. Smith.  Resistance to Causes of Death: A Study of Cancer Mortality Resistance in the Oldest Old , 1999 .

[6]  U. Ponnappan,et al.  Decreased proteasome-mediated degradation in T cells from the elderly: A role in immune senescence. , 1999, Cellular immunology.

[7]  L. Piantanelli.  Cancer and Aging: From the Kinetics of Biological Parameters to the Kinetics of Cancer Incidence and Mortality a , 1988, Annals of the New York Academy of Sciences.

[8]  A. Kudoh,et al.  Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells. , 2003, Blood.

[9]  C. K. Lee,et al.  Gene expression profile of aging and its retardation by caloric restriction. , 1999, Science.

[10]  A. Goldberg,et al.  Degradation of cell proteins and the generation of MHC class I-presented peptides. , 1999, Annual review of immunology.

[11]  C. Franceschi,et al.  Chronic antigenic stress, immunosenescence and human survivorship over the 3 last centuries: heuristic value of a mathematical model , 2003, Mechanisms of Ageing and Development.

[12]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[13]  Claudio Franceschi,et al.  Allele frequencies of +874T→A single nucleotide polymorphism at the first intron of interferon-γ gene in a group of Italian centenarians , 2002, Experimental Gerontology.

[14]  M. Masucci,et al.  Proteasome inhibitors reconstitute the presentation of cytotoxic T‐cell epitopes in Epstein‐Barr virus–associated tumors , 2002, International journal of cancer.

[15]  C. Franceschi,et al.  What studies on human longevity tell us about the risk for cancer in the oldest old: data and hypotheses on the genetics and immunology of centenarians , 2002, Experimental Gerontology.

[16]  W. Baumeister,et al.  The 26S proteasome: a molecular machine designed for controlled proteolysis. , 1999, Annual review of biochemistry.

[17]  Jonathan W. Yewdell,et al.  Immunoproteasomes Shape Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell Repertoire and Presentation of Viral Antigens , 2001, The Journal of experimental medicine.

[18]  Odile Burlet-Schiltz,et al.  The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome , 2002, The Journal of experimental medicine.

[19]  D. Ferrington,et al.  Selective Degradation of Oxidized Calmodulin by the 20 S Proteasome* , 2001, The Journal of Biological Chemistry.

[20]  N. Maclaren,et al.  Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. , 1995, American journal of human genetics.

[21]  B. Friguet,et al.  Age-dependent declines in proteasome activity in the heart. , 2002, Archives of biochemistry and biophysics.

[22]  A. Goldberg,et al.  Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules , 1994, Cell.

[23]  S. Aggarwal,et al.  Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. , 1999, Journal of immunology.

[24]  P. A. Peterson,et al.  Displacement of housekeeping proteasome subunits by MHC‐encoded LMPs: a newly discovered mechanism for modulating the multicatalytic proteinase complex. , 1994, The EMBO journal.

[25]  Mark P. Mattson,et al.  NF-κB in neuronal plasticity and neurodegenerative disorders , 2001 .

[26]  B. Friguet,et al.  Increase of oxidatively modified protein is associated with a decrease of proteasome activity and content in aging epidermal cells. , 2000, The journals of gerontology. Series A, Biological sciences and medical sciences.

[27]  C. Franceschi,et al.  Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. , 2000, Blood.

[28]  E. Pareja,et al.  Analysis of LMP and TAP polymorphisms by polymerase chain reaction-restriction fragment length polymorphism in rheumatoid arthritis , 1998, Annals of the rheumatic diseases.

[29]  Richard Weindruch,et al.  Gene-expression profile of the ageing brain in mice , 2000, Nature Genetics.

[30]  R. Huber,et al.  A gated channel into the proteasome core particle , 2000, Nature Structural Biology.

[31]  Ronald A. DePinho,et al.  The age of cancer , 2000, Nature.

[32]  A. Goldberg,et al.  26S proteasomes and immunoproteasomes produce mainly N‐extended versions of an antigenic peptide , 2001, The EMBO journal.

[33]  C. Franceschi,et al.  Age dependent impact of LMP polymorphisms on TNFα-induced apoptosis in human peripheral blood mononuclear cells , 2002, Experimental Gerontology.

[34]  A. Ciechanover,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[35]  B. Ames,et al.  The free radical theory of aging matures. , 1998, Physiological reviews.

[36]  A. Yashin,et al.  The network and the remodeling theories of aging: historical background and new perspectives , 2000, Experimental Gerontology.

[37]  C. Franceschi,et al.  The immunology of exceptional individuals: the lesson of centenarians. , 1995, Immunology today.

[38]  M. Pfreundschuh,et al.  Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. , 2002, Human gene therapy.

[39]  M. Masucci,et al.  Variations in proteasome subunit composition and enzymatic activity in B‐lymphoma lines and normal B cells , 2000, International journal of cancer.

[40]  Dmitri A. Jdanov,et al.  Have the oldest old adults ever been frail in the past? A hypothesis that explains modern trends in survival. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  P. Moss,et al.  Cytomegalovirus Seropositivity Drives the CD8 T Cell Repertoire Toward Greater Clonality in Healthy Elderly Individuals1 , 2002, The Journal of Immunology.

[42]  W. Markesbery,et al.  Impaired Proteasome Function in Alzheimer's Disease , 2000, Journal of neurochemistry.

[43]  E. Stadtman,et al.  Protein Oxidation in Aging, Disease, and Oxidative Stress* , 1997, The Journal of Biological Chemistry.

[44]  C. Franceschi,et al.  Inflamm‐aging: An Evolutionary Perspective on Immunosenescence , 2000 .

[45]  J. Keller,et al.  Proteasomes and proteasome inhibition in the central nervous system. , 2001, Free radical biology & medicine.

[46]  M. Callery,et al.  Ubiquitin proteasome pathway: implications and advances in cancer therapy. , 2001, Surgical oncology.

[47]  P. Kloetzel,et al.  The effect of the interferon‐γ‐inducible processing machinery on the generation of a naturally tumor‐associated human cytotoxic T lymphocyte epitope within a wild‐type and mutant p53 sequence context , 2002, European journal of immunology.

[48]  N. Hayashi,et al.  A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C , 2002, Journal of viral hepatitis.

[49]  V. Cerundolo,et al.  Identification of a TAP-Independent, Immunoproteasome-Dependent CD8+ T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2 , 2003, Journal of Virology.

[50]  Barnett,et al.  Association of the large multifunctional proteasome (LMP2) gene with Graves' disease is a result of linkage disequilibrium with the HLA haplotype DRB1*0304‐DQB1*02‐DQA1*0501 , 1999, Clinical endocrinology.

[51]  E. Stadtman,et al.  Oxidative modification of proteins during aging , 2001, Experimental Gerontology.

[52]  Bertrand Friguet,et al.  Impact of ageing on proteasome structure and function in human lymphocytes. , 2003, The international journal of biochemistry & cell biology.

[53]  P. Kloetzel,et al.  Ubiquitin and proteasomes: Antigen processing by the proteasome , 2001, Nature Reviews Molecular Cell Biology.

[54]  M. Masucci,et al.  Avoiding proteasomal processing: the case of EBNA1. , 2002, Current topics in microbiology and immunology.

[55]  G. Jhangri,et al.  The LMP2 polymorphism is associated with susceptibility to acute anterior uveitis in HLA-B27 positive juvenile and adult Mexican subjects with ankylosing spondylitis , 1997, Annals of the rheumatic diseases.

[56]  Bertrand Friguet,et al.  Impairment of proteasome structure and function in aging. , 2002, The international journal of biochemistry & cell biology.

[57]  Luigi Ferrucci,et al.  Serum IL‐6 Level and the Development of Disability in Older Persons , 1999, Journal of the American Geriatrics Society.

[58]  C. Franceschi,et al.  Human immunosenescence: the prevailing of innate immunity, the failing of clonotypic immunity, and the filling of immunological space. , 2000, Vaccine.

[59]  M. Leid,et al.  Ligand-induced Peroxisome Proliferator-activated Receptor α Conformational Change* , 1997, The Journal of Biological Chemistry.

[60]  L Scola,et al.  Gender-specific association between −1082 IL-10 promoter polymorphism and longevity , 2002, Genes and Immunity.

[61]  P. Jenner.  Parkinson's disease, pesticides and mitochondrial dysfunction , 2001, Trends in Neurosciences.

[62]  Richard Weindruch,et al.  Transcriptional profiles associated with aging and middle age-onset caloric restriction in mouse hearts , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  A. Polack,et al.  Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. , 1998, Journal of immunology.